Evidence map›Paper›PMID 30044647›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2018

Synthesis and pharmacological evaluation of novel isoquinoline N-sulphonylhydrazones designed as ROCK inhibitors.

Ramon Guerra de Oliveira, Fabiana Sélos Guerra, Cláudia Dos Santos Mermelstein, Patrícia Dias Fernandes, Isadora Tairinne de Sena Bastos, Fanny Nascimento Costa, Regina Cely Rodrigues Barroso, Fabio Furlan Ferreira, Carlos Alberto Manssour Fraga

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Discovery ofACS bio & med chem Au · 2026
    Article
  2. Article
  3. The Magic Methyl and Its Tricks in Drug Discovery and Development.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ramon Guerra de Oliveiraa Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Instituto de Ciências Biomédicas , Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil.ORCID http://orcid.org/0000-0002-2407-5766
Fabiana Sélos Guerrab Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas , Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil.
Cláudia Dos Santos Mermelsteind Laboratório de Diferenciação Muscular, Instituto de Ciências Biomédicas , Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil.ORCID http://orcid.org/0000-0002-8897-8526
Patrícia Dias Fernandesb Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas , Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil.ORCID http://orcid.org/0000-0001-6870-6745
Isadora Tairinne de Sena Bastose Instituto de Física , Universidade do Estado do Rio de Janeiro , Rio de Janeiro , Brazil.
Fanny Nascimento Costaf Centro de Ciências Naturais e Humanas (CCNH) , Universidade Federal do ABC (UFABC) , São Paulo , Brazil.ORCID http://orcid.org/0000-0001-9368-5640
Regina Cely Rodrigues Barrosoe Instituto de Física , Universidade do Estado do Rio de Janeiro , Rio de Janeiro , Brazil.
Fabio Furlan Ferreiraf Centro de Ciências Naturais e Humanas (CCNH) , Universidade Federal do ABC (UFABC) , São Paulo , Brazil.ORCID http://orcid.org/0000-0003-1516-1221
Carlos Alberto Manssour Fragaa Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Instituto de Ciências Biomédicas , Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil.ORCID http://orcid.org/0000-0001-6733-7079
Universidade Federal do Rio de Janeiro · BRUniversidade do Estado do Rio de Janeiro · BRUniversidade Federal do ABC · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we synthesized a new congener series of N-sulphonylhydrazones designed as candidate ROCK inhibitors using the molecular hybridization of the clinically approved drug fasudil (1) and the IKK-β inhibitor LASSBio-1524 (2). Among the synthesized compounds, the N-methylated derivative 11 (LASSBio-2065) showed the best inhibitory profile for both ROCK isoforms, with IC

Indexed as

1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAnimalsCell Line, TumorFemaleHumansHydrazonesIsoquinolinesModels, MolecularPowder DiffractionProtein Kinase Inhibitorsrho-Associated KinasesSpectrum Analysis1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinefasudilHydrazonesisoquinolineIsoquinolinesN-(4-nitrobenzylidene)-2-naphthohydrazideProtein Kinase Inhibitorsrho-Associated KinasesfasudilLASSBio-1524Molecular hybridizationN-sulphonylhydrazoneRho kinaseROCK inhibitor

Identifiers

PMID30044647
PMCPMC6060383
OpenAlexW2884171388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.